Product Description
Lexicon was developing lx-1606, an oral TPH Inhibitor for Carcinoid Syndrome. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01104415)
Mechanisms of Action: TPH Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lexicon
Company Location: THE WOODLANDS TX 77381
Company CEO: Lonnel Coats
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Malignant Carcinoid Syndrome|Serotonin Syndrome|Carcinoid Tumor|Other
Phase 2: Malignant Carcinoid Syndrome|Carcinoid Tumor|Serotonin Syndrome|Colitis, Ulcerative|Neuroendocrine Tumors
Phase 1: Malignant Carcinoid Syndrome|Serotonin Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2018-00294 | P2 |
Recruiting |
Malignant Carcinoid Syndrome|Neuroendocrine Tumors|Carcinoid Tumor|Serotonin Syndrome |
2023-10-01 |
|
| TELEPATH | P3 |
Completed |
Carcinoid Tumor|Serotonin Syndrome|Malignant Carcinoid Syndrome |
2018-09-12 |
62% |
| TELEPATH (Telotristat Etiprate â Expanded Treatment for Patients with Carcinoid Syndrome Symptoms) | P3 |
Completed |
Unknown |
2018-09-12 |
|
| TELECAST | P3 |
Completed |
Serotonin Syndrome|Carcinoid Tumor|Malignant Carcinoid Syndrome |
2016-03-29 |